Diseases /
Multiple Myeloma
Back to Diseases List
Associated Genetic Biomarkers
Overview
NCI Definition: A bone marrow-based plasma cell neoplasm characterized by a serum monoclonal protein and skeletal destruction with osteolytic lesions, pathological fractures, bone pain, hypercalcemia, and anemia. Clinical variants include non-secretory myeloma, smoldering myeloma, indolent myeloma, and plasma cell leukemia. (WHO, 2001) [1]
Multiple myelomas most frequently harbor alterations in KRAS, TP53, NRAS, TET2, and DNMT3A [2].
KRAS Mutation, TP53 Mutation, NRAS Mutation, TP53 c.217-c.1178 Missense, and TP53 Missense are the most common alterations in multiple myeloma [2].
Clinical Trials
There are 358 clinical trials for multiple myeloma, of which 298 are open and 60 are completed or closed. Of the trials that contain multiple myeloma as an inclusion criterion, 6 are early phase 1 (5 open), 136 are phase 1 (110 open), 67 are phase 1/phase 2 (54 open), 120 are phase 2 (102 open), 1 is phase 2/phase 3 (1 open), 20 are phase 3 (19 open), 1 is phase 4 (1 open), and 7 are no phase specified (6 open).
del(17)(p10), IGH-FGFR3, and t(14;16)(q32;q23) are the most frequent gene inclusion criteria for multiple myeloma clinical trials [3].
Dexamethasone, lenalidomide, and cyclophosphamide are the most common interventions in multiple myeloma clinical trials.
Significant Genes in Multiple Myeloma
ABL1 +
ABL1 is altered in 0.81% of multiple myeloma patients [2].
ABL1 is an inclusion eligibility criterion in 21 clinical trials for multiple myeloma, of which 14 are open and 7 are closed. Of the trials that contain ABL1 status and multiple myeloma as inclusion criteria, 1 is early phase 1 (1 open), 7 are phase 1 (5 open), 3 are phase 1/phase 2 (2 open), 9 are phase 2 (6 open), and 1 is no phase specified (0 open) [3].
AFF1 +
AFF1 is an inclusion eligibility criterion in 15 clinical trials for multiple myeloma, of which 10 are open and 5 are closed. Of the trials that contain AFF1 status and multiple myeloma as inclusion criteria, 7 are phase 1 (5 open), 1 is phase 1/phase 2 (1 open), 6 are phase 2 (4 open), and 1 is no phase specified (0 open) [3].
AKT1 +
AKT1 is an inclusion eligibility criterion in 1 clinical trial for multiple myeloma, of which 1 is open and 0 are closed. Of the trial that contains AKT1 status and multiple myeloma as inclusion criteria, 1 is phase 2 (1 open) [3].
AKT2 +
AKT2 is an inclusion eligibility criterion in 1 clinical trial for multiple myeloma, of which 1 is open and 0 are closed. Of the trial that contains AKT2 status and multiple myeloma as inclusion criteria, 1 is phase 2 (1 open) [3].
ARAF +
ARAF is an inclusion eligibility criterion in 1 clinical trial for multiple myeloma, of which 1 is open and 0 are closed. Of the trial that contains ARAF status and multiple myeloma as inclusion criteria, 1 is phase 1 (1 open) [3].
ASXL1 +
ASXL1 is altered in 2.45% of multiple myeloma patients [2].
ASXL1 is an inclusion eligibility criterion in 5 clinical trials for multiple myeloma, of which 4 are open and 1 is closed. Of the trials that contain ASXL1 status and multiple myeloma as inclusion criteria, 1 is early phase 1 (1 open), 1 is phase 1 (1 open), 1 is phase 1/phase 2 (1 open), and 2 are phase 2 (1 open) [3].
BCL2 +
BCL2 is altered in 0.96% of multiple myeloma patients [2].
BCL2 is an inclusion eligibility criterion in 2 clinical trials for multiple myeloma, of which 1 is open and 1 is closed. Of the trials that contain BCL2 status and multiple myeloma as inclusion criteria, 1 is phase 1 (1 open) and 1 is phase 2 (0 open) [3].
BCL6 +
BCL6 is altered in 0.48% of multiple myeloma patients [2].
BCL6 is an inclusion eligibility criterion in 2 clinical trials for multiple myeloma, of which 1 is open and 1 is closed. Of the trials that contain BCL6 status and multiple myeloma as inclusion criteria, 1 is phase 1 (1 open) and 1 is phase 2 (0 open) [3].
BCR +
BCR is an inclusion eligibility criterion in 20 clinical trials for multiple myeloma, of which 13 are open and 7 are closed. Of the trials that contain BCR status and multiple myeloma as inclusion criteria, 1 is early phase 1 (1 open), 7 are phase 1 (5 open), 3 are phase 1/phase 2 (2 open), 8 are phase 2 (5 open), and 1 is no phase specified (0 open) [3].
BRAF +
BRAF is altered in 4.05% of multiple myeloma patients [2].
BRAF is an inclusion eligibility criterion in 10 clinical trials for multiple myeloma, of which 8 are open and 2 are closed. Of the trials that contain BRAF status and multiple myeloma as inclusion criteria, 2 are phase 1 (2 open), 1 is phase 1/phase 2 (1 open), and 7 are phase 2 (5 open) [3].
CBFB +
CBFB is altered in 1.14% of multiple myeloma patients [2].
CBFB is an inclusion eligibility criterion in 6 clinical trials for multiple myeloma, of which 3 are open and 3 are closed. Of the trials that contain CBFB status and multiple myeloma as inclusion criteria, 5 are phase 1 (3 open) and 1 is no phase specified (0 open) [3].
CCND1 +
CCND1 is altered in 3.85% of multiple myeloma patients [2].
CCND1 is an inclusion eligibility criterion in 10 clinical trials for multiple myeloma, of which 7 are open and 3 are closed. Of the trials that contain CCND1 status and multiple myeloma as inclusion criteria, 1 is phase 1 (0 open), 3 are phase 1/phase 2 (2 open), 4 are phase 2 (3 open), and 2 are phase 3 (2 open) [3].
CCND3 +
CCND3 is altered in 0.95% of multiple myeloma patients [2].
CCND3 is an inclusion eligibility criterion in 3 clinical trials for multiple myeloma, of which 2 are open and 1 is closed. Of the trials that contain CCND3 status and multiple myeloma as inclusion criteria, 2 are phase 2 (1 open) and 1 is phase 3 (1 open) [3].
CDK4 +
CDK4 is altered in 0.48% of multiple myeloma patients [2].
CDK4 is an inclusion eligibility criterion in 3 clinical trials for multiple myeloma, of which 3 are open and 0 are closed. Of the trials that contain CDK4 status and multiple myeloma as inclusion criteria, 1 is phase 1/phase 2 (1 open) and 2 are phase 2 (2 open) [3].
CDK6 +
CDK6 is an inclusion eligibility criterion in 3 clinical trials for multiple myeloma, of which 3 are open and 0 are closed. Of the trials that contain CDK6 status and multiple myeloma as inclusion criteria, 1 is phase 1/phase 2 (1 open) and 2 are phase 2 (2 open) [3].
CDKN2C +
CDKN2C is altered in 2.38% of multiple myeloma patients [2].
CDKN2C is an inclusion eligibility criterion in 1 clinical trial for multiple myeloma, of which 1 is open and 0 are closed. Of the trial that contains CDKN2C status and multiple myeloma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [3].
CHEK2 +
CHEK2 is an inclusion eligibility criterion in 1 clinical trial for multiple myeloma, of which 1 is open and 0 are closed. Of the trial that contains CHEK2 status and multiple myeloma as inclusion criteria, 1 is phase 2 (1 open) [3].
DEK +
DEK is an inclusion eligibility criterion in 15 clinical trials for multiple myeloma, of which 10 are open and 5 are closed. Of the trials that contain DEK status and multiple myeloma as inclusion criteria, 1 is early phase 1 (1 open), 7 are phase 1 (5 open), 1 is phase 1/phase 2 (1 open), 5 are phase 2 (3 open), and 1 is no phase specified (0 open) [3].
ELL +
ELL is an inclusion eligibility criterion in 14 clinical trials for multiple myeloma, of which 9 are open and 5 are closed. Of the trials that contain ELL status and multiple myeloma as inclusion criteria, 7 are phase 1 (5 open), 1 is phase 1/phase 2 (1 open), 5 are phase 2 (3 open), and 1 is no phase specified (0 open) [3].
ERBB2 +
ERBB2 is altered in 0.83% of multiple myeloma patients [2].
ERBB2 is an inclusion eligibility criterion in 5 clinical trials for multiple myeloma, of which 4 are open and 1 is closed. Of the trials that contain ERBB2 status and multiple myeloma as inclusion criteria, 1 is phase 1 (1 open), 3 are phase 1/phase 2 (2 open), and 1 is phase 2 (1 open) [3].
EZH2 +
EZH2 is altered in 0.41% of multiple myeloma patients [2].
EZH2 is an inclusion eligibility criterion in 2 clinical trials for multiple myeloma, of which 0 are open and 2 are closed. Of the trials that contain EZH2 status and multiple myeloma as inclusion criteria, 1 is phase 1 (0 open) and 1 is phase 2 (0 open) [3].
FANCB +
FANCB is an inclusion eligibility criterion in 1 clinical trial for multiple myeloma, of which 1 is open and 0 are closed. Of the trial that contains FANCB status and multiple myeloma as inclusion criteria, 1 is phase 2 (1 open) [3].
FANCE +
FANCE is an inclusion eligibility criterion in 1 clinical trial for multiple myeloma, of which 1 is open and 0 are closed. Of the trial that contains FANCE status and multiple myeloma as inclusion criteria, 1 is phase 2 (1 open) [3].
FANCI +
FANCI is an inclusion eligibility criterion in 1 clinical trial for multiple myeloma, of which 1 is open and 0 are closed. Of the trial that contains FANCI status and multiple myeloma as inclusion criteria, 1 is phase 2 (1 open) [3].
FBXW7 +
FBXW7 is an inclusion eligibility criterion in 1 clinical trial for multiple myeloma, of which 1 is open and 0 are closed. Of the trial that contains FBXW7 status and multiple myeloma as inclusion criteria, 1 is phase 2 (1 open) [3].
FGF1 +
FGF1 is an inclusion eligibility criterion in 2 clinical trials for multiple myeloma, of which 2 are open and 0 are closed. Of the trials that contain FGF1 status and multiple myeloma as inclusion criteria, 2 are phase 1/phase 2 (2 open) [3].
FGF10 +
FGF10 is an inclusion eligibility criterion in 2 clinical trials for multiple myeloma, of which 2 are open and 0 are closed. Of the trials that contain FGF10 status and multiple myeloma as inclusion criteria, 2 are phase 1/phase 2 (2 open) [3].
FGF11 +
FGF11 is an inclusion eligibility criterion in 2 clinical trials for multiple myeloma, of which 2 are open and 0 are closed. Of the trials that contain FGF11 status and multiple myeloma as inclusion criteria, 2 are phase 1/phase 2 (2 open) [3].
FGF12 +
FGF12 is an inclusion eligibility criterion in 2 clinical trials for multiple myeloma, of which 2 are open and 0 are closed. Of the trials that contain FGF12 status and multiple myeloma as inclusion criteria, 2 are phase 1/phase 2 (2 open) [3].
FGF13 +
FGF13 is an inclusion eligibility criterion in 2 clinical trials for multiple myeloma, of which 2 are open and 0 are closed. Of the trials that contain FGF13 status and multiple myeloma as inclusion criteria, 2 are phase 1/phase 2 (2 open) [3].
FGF14 +
FGF14 is an inclusion eligibility criterion in 2 clinical trials for multiple myeloma, of which 2 are open and 0 are closed. Of the trials that contain FGF14 status and multiple myeloma as inclusion criteria, 2 are phase 1/phase 2 (2 open) [3].
FGF16 +
FGF16 is an inclusion eligibility criterion in 2 clinical trials for multiple myeloma, of which 2 are open and 0 are closed. Of the trials that contain FGF16 status and multiple myeloma as inclusion criteria, 2 are phase 1/phase 2 (2 open) [3].
FGF17 +
FGF17 is an inclusion eligibility criterion in 2 clinical trials for multiple myeloma, of which 2 are open and 0 are closed. Of the trials that contain FGF17 status and multiple myeloma as inclusion criteria, 2 are phase 1/phase 2 (2 open) [3].
FGF18 +
FGF18 is an inclusion eligibility criterion in 2 clinical trials for multiple myeloma, of which 2 are open and 0 are closed. Of the trials that contain FGF18 status and multiple myeloma as inclusion criteria, 2 are phase 1/phase 2 (2 open) [3].
FGF19 +
FGF19 is an inclusion eligibility criterion in 2 clinical trials for multiple myeloma, of which 2 are open and 0 are closed. Of the trials that contain FGF19 status and multiple myeloma as inclusion criteria, 2 are phase 1/phase 2 (2 open) [3].
FGF2 +
FGF2 is an inclusion eligibility criterion in 2 clinical trials for multiple myeloma, of which 2 are open and 0 are closed. Of the trials that contain FGF2 status and multiple myeloma as inclusion criteria, 2 are phase 1/phase 2 (2 open) [3].
FGF20 +
FGF20 is an inclusion eligibility criterion in 2 clinical trials for multiple myeloma, of which 2 are open and 0 are closed. Of the trials that contain FGF20 status and multiple myeloma as inclusion criteria, 2 are phase 1/phase 2 (2 open) [3].
FGF21 +
FGF21 is an inclusion eligibility criterion in 2 clinical trials for multiple myeloma, of which 2 are open and 0 are closed. Of the trials that contain FGF21 status and multiple myeloma as inclusion criteria, 2 are phase 1/phase 2 (2 open) [3].
FGF22 +
FGF22 is an inclusion eligibility criterion in 2 clinical trials for multiple myeloma, of which 2 are open and 0 are closed. Of the trials that contain FGF22 status and multiple myeloma as inclusion criteria, 2 are phase 1/phase 2 (2 open) [3].
FGF23 +
FGF23 is an inclusion eligibility criterion in 2 clinical trials for multiple myeloma, of which 2 are open and 0 are closed. Of the trials that contain FGF23 status and multiple myeloma as inclusion criteria, 2 are phase 1/phase 2 (2 open) [3].
FGF3 +
FGF3 is an inclusion eligibility criterion in 2 clinical trials for multiple myeloma, of which 2 are open and 0 are closed. Of the trials that contain FGF3 status and multiple myeloma as inclusion criteria, 2 are phase 1/phase 2 (2 open) [3].
FGF4 +
FGF4 is an inclusion eligibility criterion in 2 clinical trials for multiple myeloma, of which 2 are open and 0 are closed. Of the trials that contain FGF4 status and multiple myeloma as inclusion criteria, 2 are phase 1/phase 2 (2 open) [3].
FGF5 +
FGF5 is an inclusion eligibility criterion in 2 clinical trials for multiple myeloma, of which 2 are open and 0 are closed. Of the trials that contain FGF5 status and multiple myeloma as inclusion criteria, 2 are phase 1/phase 2 (2 open) [3].
FGF6 +
FGF6 is an inclusion eligibility criterion in 2 clinical trials for multiple myeloma, of which 2 are open and 0 are closed. Of the trials that contain FGF6 status and multiple myeloma as inclusion criteria, 2 are phase 1/phase 2 (2 open) [3].
FGF7 +
FGF7 is an inclusion eligibility criterion in 2 clinical trials for multiple myeloma, of which 2 are open and 0 are closed. Of the trials that contain FGF7 status and multiple myeloma as inclusion criteria, 2 are phase 1/phase 2 (2 open) [3].
FGF8 +
FGF8 is an inclusion eligibility criterion in 2 clinical trials for multiple myeloma, of which 2 are open and 0 are closed. Of the trials that contain FGF8 status and multiple myeloma as inclusion criteria, 2 are phase 1/phase 2 (2 open) [3].
FGF9 +
FGF9 is an inclusion eligibility criterion in 2 clinical trials for multiple myeloma, of which 2 are open and 0 are closed. Of the trials that contain FGF9 status and multiple myeloma as inclusion criteria, 2 are phase 1/phase 2 (2 open) [3].
FGFR1 +
FGFR1 is an inclusion eligibility criterion in 4 clinical trials for multiple myeloma, of which 4 are open and 0 are closed. Of the trials that contain FGFR1 status and multiple myeloma as inclusion criteria, 2 are phase 1/phase 2 (2 open) and 2 are phase 2 (2 open) [3].
FGFR2 +
FGFR2 is an inclusion eligibility criterion in 4 clinical trials for multiple myeloma, of which 4 are open and 0 are closed. Of the trials that contain FGFR2 status and multiple myeloma as inclusion criteria, 2 are phase 1/phase 2 (2 open) and 2 are phase 2 (2 open) [3].
FGFR3 +
FGFR3 is altered in 2.89% of multiple myeloma patients [2].
FGFR3 is an inclusion eligibility criterion in 32 clinical trials for multiple myeloma, of which 23 are open and 9 are closed. Of the trials that contain FGFR3 status and multiple myeloma as inclusion criteria, 1 is early phase 1 (1 open), 8 are phase 1 (5 open), 5 are phase 1/phase 2 (4 open), and 18 are phase 2 (13 open) [3].
FGFR4 +
FGFR4 is altered in 0.42% of multiple myeloma patients [2].
FGFR4 is an inclusion eligibility criterion in 3 clinical trials for multiple myeloma, of which 3 are open and 0 are closed. Of the trials that contain FGFR4 status and multiple myeloma as inclusion criteria, 2 are phase 1/phase 2 (2 open) and 1 is phase 2 (1 open) [3].
FLT3 +
FLT3 is altered in 0.81% of multiple myeloma patients [2].
FLT3 is an inclusion eligibility criterion in 22 clinical trials for multiple myeloma, of which 14 are open and 8 are closed. Of the trials that contain FLT3 status and multiple myeloma as inclusion criteria, 1 is early phase 1 (1 open), 8 are phase 1 (5 open), 2 are phase 1/phase 2 (2 open), 10 are phase 2 (6 open), and 1 is no phase specified (0 open) [3].
HRAS +
HRAS is an inclusion eligibility criterion in 3 clinical trials for multiple myeloma, of which 3 are open and 0 are closed. Of the trials that contain HRAS status and multiple myeloma as inclusion criteria, 1 is early phase 1 (1 open), 1 is phase 1 (1 open), and 1 is phase 1/phase 2 (1 open) [3].
IDH2 +
IDH2 is an inclusion eligibility criterion in 2 clinical trials for multiple myeloma, of which 1 is open and 1 is closed. Of the trials that contain IDH2 status and multiple myeloma as inclusion criteria, 1 is phase 1/phase 2 (1 open) and 1 is phase 2 (0 open) [3].
IGH +
IGH is altered in 5.98% of multiple myeloma patients [2].
IGH is an inclusion eligibility criterion in 40 clinical trials for multiple myeloma, of which 27 are open and 13 are closed. Of the trials that contain IGH status and multiple myeloma as inclusion criteria, 1 is early phase 1 (1 open), 11 are phase 1 (5 open), 6 are phase 1/phase 2 (4 open), 20 are phase 2 (15 open), and 2 are phase 3 (2 open) [3].
JAK2 +
JAK2 is altered in 1.62% of multiple myeloma patients [2].
JAK2 is an inclusion eligibility criterion in 2 clinical trials for multiple myeloma, of which 1 is open and 1 is closed. Of the trials that contain JAK2 status and multiple myeloma as inclusion criteria, 1 is early phase 1 (1 open) and 1 is phase 2 (0 open) [3].
KIT +
KIT is altered in 0.4% of multiple myeloma patients [2].
KIT is an inclusion eligibility criterion in 10 clinical trials for multiple myeloma, of which 7 are open and 3 are closed. Of the trials that contain KIT status and multiple myeloma as inclusion criteria, 5 are phase 1 (3 open), 4 are phase 2 (4 open), and 1 is no phase specified (0 open) [3].
KMT2A +
KMT2A is altered in 2.52% of multiple myeloma patients [2].
KMT2A is an inclusion eligibility criterion in 17 clinical trials for multiple myeloma, of which 12 are open and 5 are closed. Of the trials that contain KMT2A status and multiple myeloma as inclusion criteria, 1 is early phase 1 (1 open), 7 are phase 1 (5 open), 2 are phase 1/phase 2 (2 open), 6 are phase 2 (4 open), and 1 is no phase specified (0 open) [3].
KRAS +
KRAS is altered in 12.96% of multiple myeloma patients [2].
KRAS is an inclusion eligibility criterion in 5 clinical trials for multiple myeloma, of which 4 are open and 1 is closed. Of the trials that contain KRAS status and multiple myeloma as inclusion criteria, 1 is early phase 1 (1 open), 2 are phase 1 (2 open), 1 is phase 1/phase 2 (1 open), and 1 is phase 2 (0 open) [3].
MAF +
MAF is altered in 1.79% of multiple myeloma patients [2].
MAF is an inclusion eligibility criterion in 27 clinical trials for multiple myeloma, of which 18 are open and 9 are closed. Of the trials that contain MAF status and multiple myeloma as inclusion criteria, 1 is early phase 1 (1 open), 8 are phase 1 (5 open), 3 are phase 1/phase 2 (2 open), and 15 are phase 2 (10 open) [3].
MAFB +
MAFB is altered in 1.77% of multiple myeloma patients [2].
MAFB is an inclusion eligibility criterion in 18 clinical trials for multiple myeloma, of which 11 are open and 7 are closed. Of the trials that contain MAFB status and multiple myeloma as inclusion criteria, 5 are phase 1 (3 open), 2 are phase 1/phase 2 (1 open), and 11 are phase 2 (7 open) [3].
MAP2K2 +
MAP2K2 is an inclusion eligibility criterion in 1 clinical trial for multiple myeloma, of which 1 is open and 0 are closed. Of the trial that contains MAP2K2 status and multiple myeloma as inclusion criteria, 1 is phase 1 (1 open) [3].
MAPK1 +
MAPK1 is an inclusion eligibility criterion in 1 clinical trial for multiple myeloma, of which 1 is open and 0 are closed. Of the trial that contains MAPK1 status and multiple myeloma as inclusion criteria, 1 is phase 1 (1 open) [3].
MCPH1 +
MCPH1 is an inclusion eligibility criterion in 1 clinical trial for multiple myeloma, of which 1 is open and 0 are closed. Of the trial that contains MCPH1 status and multiple myeloma as inclusion criteria, 1 is phase 2 (1 open) [3].
MECOM +
MECOM is altered in 0.84% of multiple myeloma patients [2].
MECOM is an inclusion eligibility criterion in 21 clinical trials for multiple myeloma, of which 16 are open and 5 are closed. Of the trials that contain MECOM status and multiple myeloma as inclusion criteria, 1 is early phase 1 (1 open), 10 are phase 1 (8 open), 1 is phase 1/phase 2 (1 open), 8 are phase 2 (6 open), and 1 is no phase specified (0 open) [3].
MLF1 +
MLF1 is an inclusion eligibility criterion in 8 clinical trials for multiple myeloma, of which 7 are open and 1 is closed. Of the trials that contain MLF1 status and multiple myeloma as inclusion criteria, 3 are phase 1 (3 open), 1 is phase 1/phase 2 (1 open), and 4 are phase 2 (3 open) [3].
MLLT1 +
MLLT1 is an inclusion eligibility criterion in 14 clinical trials for multiple myeloma, of which 9 are open and 5 are closed. Of the trials that contain MLLT1 status and multiple myeloma as inclusion criteria, 7 are phase 1 (5 open), 1 is phase 1/phase 2 (1 open), 5 are phase 2 (3 open), and 1 is no phase specified (0 open) [3].
MLLT10 +
MLLT10 is an inclusion eligibility criterion in 14 clinical trials for multiple myeloma, of which 9 are open and 5 are closed. Of the trials that contain MLLT10 status and multiple myeloma as inclusion criteria, 7 are phase 1 (5 open), 1 is phase 1/phase 2 (1 open), 5 are phase 2 (3 open), and 1 is no phase specified (0 open) [3].
MLLT3 +
MLLT3 is an inclusion eligibility criterion in 14 clinical trials for multiple myeloma, of which 9 are open and 5 are closed. Of the trials that contain MLLT3 status and multiple myeloma as inclusion criteria, 7 are phase 1 (5 open), 1 is phase 1/phase 2 (1 open), 5 are phase 2 (3 open), and 1 is no phase specified (0 open) [3].
MLLT4 +
MLLT4 is an inclusion eligibility criterion in 14 clinical trials for multiple myeloma, of which 9 are open and 5 are closed. Of the trials that contain MLLT4 status and multiple myeloma as inclusion criteria, 7 are phase 1 (5 open), 1 is phase 1/phase 2 (1 open), 5 are phase 2 (3 open), and 1 is no phase specified (0 open) [3].
MYC +
MYC is altered in 1.9% of multiple myeloma patients [2].
MYC is an inclusion eligibility criterion in 5 clinical trials for multiple myeloma, of which 3 are open and 2 are closed. Of the trials that contain MYC status and multiple myeloma as inclusion criteria, 3 are phase 1 (2 open) and 2 are phase 2 (1 open) [3].
MYH11 +
MYH11 is an inclusion eligibility criterion in 6 clinical trials for multiple myeloma, of which 3 are open and 3 are closed. Of the trials that contain MYH11 status and multiple myeloma as inclusion criteria, 5 are phase 1 (3 open) and 1 is no phase specified (0 open) [3].
NF1 +
NF1 is altered in 0.47% of multiple myeloma patients [2].
NF1 is an inclusion eligibility criterion in 2 clinical trials for multiple myeloma, of which 2 are open and 0 are closed. Of the trials that contain NF1 status and multiple myeloma as inclusion criteria, 1 is phase 1 (1 open) and 1 is phase 2 (1 open) [3].
NF2 +
NF2 is an inclusion eligibility criterion in 1 clinical trial for multiple myeloma, of which 1 is open and 0 are closed. Of the trial that contains NF2 status and multiple myeloma as inclusion criteria, 1 is phase 2 (1 open) [3].
NFKB2 +
NFKB2 is an inclusion eligibility criterion in 1 clinical trial for multiple myeloma, of which 1 is open and 0 are closed. Of the trial that contains NFKB2 status and multiple myeloma as inclusion criteria, 1 is phase 2 (1 open) [3].
NPM1 +
NPM1 is an inclusion eligibility criterion in 8 clinical trials for multiple myeloma, of which 7 are open and 1 is closed. Of the trials that contain NPM1 status and multiple myeloma as inclusion criteria, 3 are phase 1 (3 open), 1 is phase 1/phase 2 (1 open), and 4 are phase 2 (3 open) [3].
NRAS +
NRAS is altered in 8.5% of multiple myeloma patients [2].
NRAS is an inclusion eligibility criterion in 5 clinical trials for multiple myeloma, of which 4 are open and 1 is closed. Of the trials that contain NRAS status and multiple myeloma as inclusion criteria, 1 is early phase 1 (1 open), 2 are phase 1 (2 open), 1 is phase 1/phase 2 (1 open), and 1 is phase 2 (0 open) [3].
NTRK2 +
NTRK2 is an inclusion eligibility criterion in 1 clinical trial for multiple myeloma, of which 1 is open and 0 are closed. Of the trial that contains NTRK2 status and multiple myeloma as inclusion criteria, 1 is phase 2 (1 open) [3].
NUP214 +
NUP214 is an inclusion eligibility criterion in 15 clinical trials for multiple myeloma, of which 10 are open and 5 are closed. Of the trials that contain NUP214 status and multiple myeloma as inclusion criteria, 1 is early phase 1 (1 open), 7 are phase 1 (5 open), 1 is phase 1/phase 2 (1 open), 5 are phase 2 (3 open), and 1 is no phase specified (0 open) [3].
PBX1 +
PBX1 is altered in 0.89% of multiple myeloma patients [2].
PBX1 is an inclusion eligibility criterion in 9 clinical trials for multiple myeloma, of which 7 are open and 2 are closed. Of the trials that contain PBX1 status and multiple myeloma as inclusion criteria, 3 are phase 1 (3 open), 1 is phase 1/phase 2 (1 open), and 5 are phase 2 (3 open) [3].
PML +
PML is an inclusion eligibility criterion in 1 clinical trial for multiple myeloma, of which 1 is open and 0 are closed. Of the trial that contains PML status and multiple myeloma as inclusion criteria, 1 is phase 1 (1 open) [3].
PTEN +
PTEN is an inclusion eligibility criterion in 2 clinical trials for multiple myeloma, of which 2 are open and 0 are closed. Of the trials that contain PTEN status and multiple myeloma as inclusion criteria, 2 are phase 2 (2 open) [3].
RAD51B +
RAD51B is an inclusion eligibility criterion in 1 clinical trial for multiple myeloma, of which 1 is open and 0 are closed. Of the trial that contains RAD51B status and multiple myeloma as inclusion criteria, 1 is phase 2 (1 open) [3].
RAF1 +
RAF1 is an inclusion eligibility criterion in 1 clinical trial for multiple myeloma, of which 1 is open and 0 are closed. Of the trial that contains RAF1 status and multiple myeloma as inclusion criteria, 1 is phase 1 (1 open) [3].
RARA +
RARA is an inclusion eligibility criterion in 1 clinical trial for multiple myeloma, of which 1 is open and 0 are closed. Of the trial that contains RARA status and multiple myeloma as inclusion criteria, 1 is phase 1 (1 open) [3].
RET +
RET is an inclusion eligibility criterion in 2 clinical trials for multiple myeloma, of which 2 are open and 0 are closed. Of the trials that contain RET status and multiple myeloma as inclusion criteria, 2 are phase 2 (2 open) [3].
RHEB +
RHEB is an inclusion eligibility criterion in 1 clinical trial for multiple myeloma, of which 1 is open and 0 are closed. Of the trial that contains RHEB status and multiple myeloma as inclusion criteria, 1 is phase 2 (1 open) [3].
RPN1 +
RPN1 is an inclusion eligibility criterion in 21 clinical trials for multiple myeloma, of which 16 are open and 5 are closed. Of the trials that contain RPN1 status and multiple myeloma as inclusion criteria, 1 is early phase 1 (1 open), 10 are phase 1 (8 open), 1 is phase 1/phase 2 (1 open), 8 are phase 2 (6 open), and 1 is no phase specified (0 open) [3].
RUNX1 +
RUNX1 is an inclusion eligibility criterion in 9 clinical trials for multiple myeloma, of which 6 are open and 3 are closed. Of the trials that contain RUNX1 status and multiple myeloma as inclusion criteria, 1 is early phase 1 (1 open), 5 are phase 1 (3 open), 1 is phase 1/phase 2 (1 open), 1 is phase 2 (1 open), and 1 is no phase specified (0 open) [3].
RUNX1T1 +
RUNX1T1 is altered in 1.49% of multiple myeloma patients [2].
RUNX1T1 is an inclusion eligibility criterion in 6 clinical trials for multiple myeloma, of which 3 are open and 3 are closed. Of the trials that contain RUNX1T1 status and multiple myeloma as inclusion criteria, 5 are phase 1 (3 open) and 1 is no phase specified (0 open) [3].
SRC +
SRC is altered in 0.64% of multiple myeloma patients [2].
SRC is an inclusion eligibility criterion in 2 clinical trials for multiple myeloma, of which 2 are open and 0 are closed. Of the trials that contain SRC status and multiple myeloma as inclusion criteria, 1 is phase 1 (1 open) and 1 is phase 2 (1 open) [3].
TCF3 +
TCF3 is altered in 0.83% of multiple myeloma patients [2].
TCF3 is an inclusion eligibility criterion in 9 clinical trials for multiple myeloma, of which 7 are open and 2 are closed. Of the trials that contain TCF3 status and multiple myeloma as inclusion criteria, 3 are phase 1 (3 open), 1 is phase 1/phase 2 (1 open), and 5 are phase 2 (3 open) [3].
TP53 +
TP53 is altered in 8.91% of multiple myeloma patients [2].
TP53 is an inclusion eligibility criterion in 20 clinical trials for multiple myeloma, of which 14 are open and 6 are closed. Of the trials that contain TP53 status and multiple myeloma as inclusion criteria, 1 is early phase 1 (1 open), 8 are phase 1 (5 open), 2 are phase 1/phase 2 (2 open), 8 are phase 2 (6 open), and 1 is no phase specified (0 open) [3].
VHL +
VHL is an inclusion eligibility criterion in 1 clinical trial for multiple myeloma, of which 1 is open and 0 are closed. Of the trial that contains VHL status and multiple myeloma as inclusion criteria, 1 is phase 2 (1 open) [3].
WHSC1 +
WHSC1 is altered in 1.97% of multiple myeloma patients [2].
WHSC1 is an inclusion eligibility criterion in 12 clinical trials for multiple myeloma, of which 8 are open and 4 are closed. Of the trials that contain WHSC1 status and multiple myeloma as inclusion criteria, 3 are phase 1 (2 open), 1 is phase 1/phase 2 (0 open), and 8 are phase 2 (6 open) [3].
Disease Details
References
1. National Cancer Institute. NCI Thesaurus Version 18.11d. https://ncit.nci.nih.gov/ncitbrowser/ [2018-08-28]. [2018-09-21].
2. The AACR Project GENIE Consortium. AACR Project GENIE: powering precision medicine through an international consortium. Cancer Discovery. 2017;7(8):818-831. Dataset Version 8. This dataset does not represent the totality of the genetic landscape; see paper for more information.
3. All assertions and clinical trial landscape data are curated from primary sources. You can read more about the curation process here.
